Man Group plc Sells 94,185 Shares of Janux Therapeutics, Inc. $JANX

Man Group plc cut its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 27.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 248,801 shares of the company’s stock after selling 94,185 shares during the quarter. Man Group plc’s holdings in Janux Therapeutics were worth $3,822,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new stake in shares of Janux Therapeutics during the second quarter worth approximately $2,646,000. ADAR1 Capital Management LLC boosted its holdings in shares of Janux Therapeutics by 41.0% in the 2nd quarter. ADAR1 Capital Management LLC now owns 420,881 shares of the company’s stock worth $6,465,000 after acquiring an additional 122,335 shares in the last quarter. Algert Global LLC grew its position in Janux Therapeutics by 150.5% during the 2nd quarter. Algert Global LLC now owns 1,110,889 shares of the company’s stock worth $17,063,000 after acquiring an additional 667,492 shares during the last quarter. Allstate Corp acquired a new stake in Janux Therapeutics during the 2nd quarter valued at $284,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Janux Therapeutics by 12.1% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 133,870 shares of the company’s stock valued at $2,056,000 after purchasing an additional 14,494 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on JANX. Truist Financial reissued a “buy” rating and issued a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a research note on Thursday, June 25th. Piper Sandler lowered their target price on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Wedbush cut their price target on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, May 8th. Stifel Nicolaus set a $35.00 price target on shares of Janux Therapeutics in a research report on Friday, August 7th. Finally, TD Cowen raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Janux Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $36.46.

Insider Activity

In other news, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the transaction, the insider directly owned 75,941 shares in the company, valued at $1,065,452.23. This trade represents a 5.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by corporate insiders.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX opened at $18.03 on Monday. Janux Therapeutics, Inc. has a 1-year low of $12.12 and a 1-year high of $35.34. The business has a 50-day moving average price of $16.12 and a two-hundred day moving average price of $14.82. The stock has a market capitalization of $1.10 billion, a P/E ratio of -10.99 and a beta of 2.50.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to analyst estimates of $19.07 million. As a group, equities analysts predict that Janux Therapeutics, Inc. will post -1.76 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.